secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0001818331-22-000035
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sema4 reports Q4 revenue $57.8M, restates prior-period financials due to expense classification errors
--------------------------------------------------------------------------------

- Q4 2021 revenue $57.8M (up 24% ex-COVID); full-year revenue $212.2M. Net loss $40.2M Q4, $245.4M full year.
- Test volumes (ex-COVID) grew 37% YoY to 82,966; Oncology volumes up 142%, Women's Health up 33%.
- Restating audited financials for 2020 and 2019, and unaudited quarters in 2021/2020, due to expense misclassification and out-of-period cost recognition.
- 2022 guidance: total revenue $215-225M, test volume growth >20% ex-COVID, adjusted gross margin >10%; excludes pending GeneDx acquisition.
- Cash $400.6M at Dec 31, 2021; pending $200M PIPE and GeneDx acquisition expected to close Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000035/0001818331-22-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000035/smfr-20220310.htm
  HTML page:      https://secwatch.observer/filing/0001818331-22-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer